[NH:1]1[CH2:6][CH2:5][C:4]2([C:14]3[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=3)[NH:8][C:7]2=[O:15])[CH2:3][CH2:2]1.Cl.[C:17]([C:19]1[CH:32]=[CH:31][C:22]([CH2:23][N:24]2[C:28]([CH2:29]Cl)=[CH:27][N:26]=[CH:25]2)=[CH:21][CH:20]=1)#[N:18].C(N(CC)CC)C>C(#N)C.C(OCC)(=O)C>[N:1]1([CH2:29][C:28]2[N:24]([CH2:23][C:22]3[CH:31]=[CH:32][C:19]([C:17]#[N:18])=[CH:20][CH:21]=3)[CH:25]=[N:26][CH:27]=2)[CH2:6][CH2:5][C:4]2([C:14]3[C:9](=[CH:10][CH:11]=[CH:12][CH:13]=3)[NH:8][C:7]2=[O:15])[CH2:3][CH2:2]1A solution of spiro[3H-indole-3,4′-piperidin]-2(1H)-one, as described above in Step B, (110 mg, 0.54 mmol), 1-(4-cyanobenzyl)-5-chloromethylimidazole hydrochloride salt, as described in Example 1, Alternate Step A, (134 mg, 0.50 mmol), and triethylamine (0.21 mL, 1.5 mmol) in anhydrous acetonitrile (1.5 mL) was stirred at room temp. for 15 hours. The resulting mixture was diluted with ethyl acetate and the solution washed with sat'd aqueous sodium carbonate, dried (anhyd. sodium sulfate), filtered and concentrated under vacuum. The resulting residue was triturated with ethyl acetate to give a white solid which was collected to afford the title compound as a crystalline freebase, mp: 245-247° C.